Home > Healthcare > Pharmaceuticals > Finished Drug Form > Silver Wound Dressing Market

Silver Wound Dressing Market Trends

Report ID: GMI12165
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Silver Wound Dressing Market Trends

Recent innovations in wound dressing technology have introduced products with improved properties, such as extended antimicrobial effects, increased absorption, and enhanced moisture retention. Additionally, silver dressings are now available in various forms—including foams, hydrogels, and hydrocolloids—to address different wound types and healing stages. These advancements are driving market growth as manufacturers enhance product efficacy and usability, making wound dressings suitable for both home care and clinical settings.

For instance, in May 2024, Convatec, a leading medical products and technologies company, announced clinical study results from a recent multinational randomized controlled trial (RCT) showcasing significant advancements in the healing of venous leg ulcers with AQUACEL Ag+ Extra compared to standard-of-care dressings. Consequently, the rising demand for advanced wound care products, along with increasing healthcare awareness and expenditure, is expected to drive substantial growth in the silver dressings market over the next few years.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of silver wound dressing reached USD 1 billion in 2023 and is set to grow at a 5.8% CAGR from 2024 to 2032, driven by the increasing prevalence of chronic wounds and advancements in wound care technologies.

The sheets segment dominated the market with USD 367.9 million in 2023, primarily due to the rising incidence of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

The surgical wounds segment accounted for a significant market share of 31.3% in 2023, fueled by the global increase in surgeries due to lifestyle-related diseases, trauma, and elective procedures.

The U.S. market is expected to grow at a 5.7% CAGR, reaching USD 666.6 million by 2032, driven by the increasing incidence of hospital-acquired infections (HAIs).

Prominent players in the industry include 3M Company, Advanced Medical Solutions Group, B Braun Melsungen, Bravida Medical, Convatec, Coloplast, DermaRite Industries, Ethicon (Johnson and Johnson), Ferris Mfg, Medline Industries, Monlycke Health Care, and Smith & Nephew.